AFT Pharmaceuticals has reported record sales for the first half of the financial year, driven by double-digit growth in the Australasian market.
However, international and Asian sales were lower because of specific one-off factors, including a temporary reduction in demand from major customers and a doctors' strike in South Korea.
The company expects a strong recovery in the second half of the year, aided by the resolution of these disruptions and new product launches.
AFT Pharmaceuticals anticipates its operating profit for the full year to be in the range of $15 million to $20m.
The company's half-year operating revenue increased by 4% to $86.7m, while it reported an operating loss of $1.8m, compared to a profit of $3.3m in the same period last year.
AFT Pharmaceuticals' net debt decreased by 37% to $18.9m.
See more
